'Fluorescent markers' to illuminate cancer begins Phase 3 clinical trials

(Purdue University) Purdue-discovered intraoperative molecular imaging used to illuminate and target non-small-cell lung cancer shows improved outcomes for 26% of patients in multi-institutional Phase 2 clinical trial, receives FDA fast track.

https://www.eurekalert.org/pub_releases/2020-02/pu-mt020620.php

Source: EurekAlert! - Medicine and Health - February 6, 2020 Category: International Medicine & Public Health Source Type: news